Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026)

Rigel Pharmaceuticals has reported Non-Current Debt for 8 years, with the latest figure at $44.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed 0.17% year-over-year to $44.9 million; the trailing twelve-month figure through Mar 2026 stood at $44.9 million (changed 0.17% YoY), and the FY2025 full-year result was $22.5 million, down 57.1% from the prior year.
• Non-Current Debt for Q1 2026 stood at $44.9 million, up from $22.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $59.8 million in Q3 2024, with the low at $22.5 million in Q4 2025.
• Average Non-Current Debt over 5 years is $45.1 million, with a median of $44.9 million recorded in 2024.
• Year-over-year, Non-Current Debt soared 99.68% in 2023 and sank 57.1% in 2025.
• Tracing RIGL's Non-Current Debt over 5 years: stood at $39.4 million in 2022, then surged by 32.76% to $52.4 million in 2023, then grew by 0.07% to $52.4 million in 2024, then slumped by 57.1% to $22.5 million in 2025, then jumped by 99.52% to $44.9 million in 2026.
• The last three Non-Current Debt figures came in at $44.9 million (Q1 2026), $22.5 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.

Peer Comparison